Grant-funded, investigator-initiated trials fail to bounce back from COVID as 50% of research staff left for higher-paying jobs

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Academic cancer centers are facing severe staffing shortages after three years of personnel attrition during the COVID-19 pandemic—resulting in depressed levels of patient accrual to investigator-initiated and grant-funded clinical trials.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Matthew Bin Han Ong
Matthew Bin Han Ong
Table of Contents

YOU MAY BE INTERESTED IN

A new statistical tool that combines multiple clinical and pathologic factors with a patient’s 21-gene Oncotype DX Breast Recurrence Score result provides more accurate estimates about that patient’s breast cancer prognosis and their potential benefit from chemotherapy than either the Recurrence Score result or clinical factors alone, a SWOG Cancer Research study found.
Matthew Bin Han Ong
Matthew Bin Han Ong

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login